Eyeing the 'translatome,' Pfizer ties another knot with biotech partner for preclinical, next-gen targeted therapies
After closely following eFFECTOR Therapeutics’ work on next-gen targeted cancer therapies in the past two years, chipping in its own venture dollars and inking an I/O combo collaboration with its PD-L1, Pfizer is betting on a second drug candidate from the biotech partner.
The preclinical deal starts relatively small — $15 million upfront — but Pfizer has committed to $492 million in R&D funding and milestones, as well as royalties and an option to co-promote in the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.